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Available online 19 July 2013Persons at risk for autosomal dominant neurodegenerative diseases provide the opportunity to
efficiently test preventive interventions. Only a minority of such persons, however, choose to
undergo revealing genetic testing, presenting a challenge to enrollment. Thirty-four preclinical
Latinos (n = 26) and non-Latinos at risk for familial Alzheimer's disease (FAD) unaware of their
genetic statuswere administered a questionnaire exploring their interest in undergoing revealing
genetic testing at baseline and in the context of eligibility for four prevention trials of increasing
invasiveness. Forty-four percent of subjects expressed a baseline interest in undergoing revealing
testing which increased to 85% in order to be eligible for a study of an oral drug “felt to be very
safe.” If there were a 50% chance of receiving placebo, this number dropped to 62% (p = 0.02).
Among those not interested in a study involving a 50% chance of receiving placebo, a range of 5%
to 40% chance of receiving placebo was given as acceptable. For more invasive studies, living in
the United States (as opposed toMexico) positively influenced the likelihood of participating. Our
data suggest that clinical trial designs inwhich personsmust confront their genetic status prior to
enrollment are feasible. Study designs to minimize the likelihood of being placed on placebo or
provide the eventual administration of the drug through open-label extensions should be
considered.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Keywords:
FAD
Pre-symptomatic
Genetic
Testing
Trials
Preventionearly-onset familial
totemporal dementia
rology, Easton Center
e., #200, Los Angeles,
794 3148.
ingman).
r Inc. Open access under CC BY-NC-1. Introduction
Dementia affects approximately twenty-four million people
worldwide [1],with Alzheimer disease (AD) comprising 60–70%
of all cases [2]. The clinical manifestations of AD are preceded
by a 15- to 20-year period of silent pathology that includes
accumulation of fibrillar beta amyloid and development of
neurofibrillary tangles and ultimately results in synaptic and
neuronal loss that produce cognitive impairment [3]. Because
reversing the neuronal loss caused by AD is difficult and may
ultimately prove impossible, there are increased efforts at
identifying interventions to prevent the clinical manifestation
of AD. Delaying onset of AD dementia by 2 yearswould lead to 2ND license.
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AD prevention studies, however, present several challenges.
For prevention trials to be informative, sufficient numbers of
participants must develop dementia to power comparisons of
intervention to placebo. Prevention trialsmay therefore “enrich”
the study population for personsmore likely to developAD (e.g.,
with a family history of the disorder [5,6]), but even so, they
must recruit several thousand participants and follow them for
many years [7]. Studying a population in whom the disease can
be more reliably predicted would greatly augment the perfor-
mance of prevention studies.
Early-onset familial AD (FAD) is a rare, fully penetrant,
autosomal dominant form of AD [8] due to mutations in the
PSEN1, APP, or PSEN2 genes. The typical age of onset is in the
mid-30s to late-50s [5] and can be highly consistent within
mutation-carrying kindreds [9]. Although affected individ-
uals or pre-symptomatic individuals at risk for a known
familial mutation can undergo genetic testing, such testing is
not currently widely offered, at least in part due to the
unavailability of effective interventions [10].
One way to perform efficient prevention trials in AD is to
enroll presymptomatic FAD mutation carriers. The number
of such individuals who decide to undergo predictive, pre-
symptomatic testing, however, is relatively low [11]. In one
study, less than 10% of eligible persons from familieswith known
pathogenicmutations for frontotemporal dementia (FTD) or FAD
decided to undergo predictive testing [12]. As persons at risk for
FAD do not typically desire to undergo genetic testing, one
cannot identify appropriate subjects in whom exposure to a
potentially toxic treatment is justified [11]. Additionally, the risk
of being placed into the placebo armof a controlled studymaybe
too high for an individual to risk learning that they will develop
the disease [11]. The decision to undergo genetic testing prior to
such trial participation is therefore a difficult one and performing
prevention studies ethically such that subjects are truly informed
regarding the scope of risks and benefits presents challenges
[11].
The design of prevention trials in FAD will be improved by
enhanced understanding of protocol features that affect at-risk
persons' desire to undergo genetic testing. We examined what
aspects of study design are important to individuals at risk for
FAD in determining whether they would be willing to undergo
genetic testing, learn the results, and participate in the study.
We also explored the effect of potential assignment to placebo
and participants' reasoning behind their decisions.
2. Materials and methods
2.1. Participants
Thirty-four participants of a comprehensive study of pre-
and symptomatic FAD being performed at UCLA completed a
questionnaire exploring their interest in undergoing genetic
testing in multiple contexts. All participants were at 50% risk of
inheriting FADdue to knownmutations in PSEN1, APP, or PSEN2
by virtue of being the first-degree relative of someone affected
by the illness in a family shown to carry such a mutation. This
observational study seeks to characterize cognitive, behavioral,
imaging (via positron emission tomography and multi-modal
magnetic resonance imaging), and biochemical (plasma and
cerebrospinal fluid) changes occurring during the pre- andsymptomatic stages of FAD. In this study, participants undergo
genetic testing for themutation forwhich they are at risk but in
the context of the study are not told the results. All participants
are offered clinical testing outside the study at no expense to
them. Only non-demented participants (Clinical Dementia
Rating Scale [13] score less than 1) who were unaware of
their mutation status were administered the questionnaire.
The population included Mexicans living in Mexico (n = 10),
Mexican Americans (n = 9), other Latinos residing in the
United States (n = 7), and non-Latino Caucasians residing in
the United States (n = 8). The questionnaire was created in
both English and Spanish, and subjects completed it in the
language in which they were most proficient. Questionnaires
were completed during a research visit or at home and were
returned by mail. All subjects sent the questionnaire by mail
(n = 10) or asked to complete the questionnaire during the
research visit (n = 24) completed the questionnaire. No
additional incentives were provided to subjects to complete
this sub-study. All study procedures were approved by the
UCLA Institutional Review Board.
2.2. Questionnaire
Awritten questionnaire collected background demographic
information and explored at-risk persons' baseline attitudes
about genetic testing and clinical trial participation. Willing-
ness to undergo genetic testing in the context of eligibility for
four hypothetical prevention trials of “promising interven-
tions” of increasing level of invasiveness was then explored.
These hypothetical studies were modeled after currently
ongoing trials in AD. In each of the four hypothetical scenarios,
it was explicitly explained that subjects would have to learn
their genetic status and only mutation carriers would be
eligible to participate. Subjects read that “In such studies, it
may be necessary to assign some subjects to receive placebo
(an inert, inactive intervention, or ‘sugar pill') in order to
demonstrate that persons receiving the active drug develop AD
at a lower rate.”
The questionnaire was initially written in English and
then translated into Spanish by a fluently bilingual person
of Puerto Rican origin (author LDM). It was then back-
translated to English by a bilingual native of Colombia
working as a neuropsychologist in Mexico (author YA-R).
Differences in the back-translated version were discussed
and edits made to reconcile discrepancies.
2.2.1. Hypothetical study 1
Study 1 was described as follows: “A drug company is
looking for participants for a research study for a medication
with substantial promise in preventing AD. The medication
has been studied extensively in animals and humans and is
felt to be very safe. The treatment is a pill, taken twice a day
that would most likely be required for the rest of your life.”
2.2.2. Hypothetical study 2
Study 2 was described as follows: “A research study is
looking at the effects of a vaccination that is given once per
year for the rest of your life and hopefully will provide
protection from the development of AD. Earlier studies of
this vaccination in people have shown a 5% risk of brain
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(like a stroke) in 1% of subjects.”
2.2.3. Hypothetical study 3
Study 3 was described as follows: “A drug company wants
to test a medication that would be administered intrave-
nously every three months for the rest of your life. Similar to
the vaccination study, prior research in people has shown a
5% risk of brain inflammation that leads to permanent
neurological disability (like a stroke) in 1% of subjects.”
2.2.4. Hypothetical study 4
Study 4 was described as follows: “A research study is
looking for participants for a high-risk clinical trial involving
brain surgery. In this study, a neurosurgeon would drill small
holes, one on each side of your skull while you are asleep
under anesthesia. They would then implant the cells deep
into your brain. The risks of the surgery and anesthesia can be
high, and may include death. Results cannot be guaranteed.
However, if the treatment worked, you would not develop
AD or it would develop later in life. Therefore, the benefits
could be as high as the risks.”
After each hypothetical study description, participants
were asked, “Knowing that there is a potential (but not a
guarantee) to stop the development of AD, but that you
would have to be told that you in fact are carrying the gene
that causes FAD, would you participate in this study?” If
subjects indicated they were interested in a given scenario,
they were then asked to endorse, or not, the reasons. They
were given the following options: “the possible benefits
outweigh the risks of being made aware of genetic status,”
“to help future generations,” or “other,” and they were given
space to provide their reasons. If they chose not to participate
in a given scenario, they were also asked to endorse, or not,
the following options, “I do not wish to know my genetic
status and the possible benefits aren't worth it, “The risks and
side effects are too high to justify possible benefits,” “I do not
want to risk being told I am a carrier and then be placed in
the placebo group,” and “Other” and were given space to
provide their reasons. Subsequent questions explored how
the possibility of a 50% risk of being assigned to placebo
would affect their decision, and if that was unacceptable,
what an acceptable chance of receiving placebo would be.
2.3. Statistical analysis
Descriptive statistics, chi-square analyses, Fisher's exact test
and theMcNemar test for paired proportions were used where
appropriate. Variables assessed regarding their impact on
desire to be tested and participate in each trial included age,Table 1
Demographic information for those wanting or possibly wanting to know their F
mutation status.
Currently want or
their FAD mutation
No. female (%) 19 (86%)
Age (SD) 33.7 (10.5)
Education in years (SD) 13.7 (3.2)
No. Latino (%, the remainder are non-Latino Caucasians) 11 (50%)years of education, gender, country of residence, whether they
were employed, currently have children or plan to have more
children.
3. Results
3.1. Demographics
Thirty-four participants completed the questionnaire, 10
in Spanish and the remainder in English. The mean age of
responders was 35.3 ± 10.3 (range, 19–62). Twenty-six
participants (76%) were female and 16 (47.1%) reported
having children. Six respondents who did not have children
at the time of the study reported plans to have children in the
future. Years of education completed ranged from 6 years to
19 years with a mean of 13.9 ± 3.0. Twenty-six (76.5%)
participants were employed at the time of completing the
questionnaire and 10 (29.4%) reported still being in school.
3.2. Questionnaire responses
At baseline, 15 (44%) of 34 respondents reported a desire to
learn their genetic status, 12 (35%) did not want to learn their
genetic status, and 7 (21%) reported they may be interested in
learning their genetic status (Table 1). There was a trend
toward females more frequently responding “yes” or “maybe”
to undergoing genetic testing at baseline (73% vs. 38% of men,
p = 0.07). Eighteen (82%) of 22 respondents with children
reported they would consider testing if their children asked
them to do so, 1 (5%) reported theywould not consider testing,
and 3 (14%) reported they might consider testing. Also at
baseline, 21 (62%) respondents reported that they would be
interested in participating in a clinical trial, 9 (26%) reported
they may be interested, 3 (9%) reported they would not be
interested, and 1 (3%) did not respond to the question. All 16
respondents with children expressed a potential interest in
participating in a clinical trial (replied “yes” or “maybe”)
relative to 14/17 (82.4%) respondents without children (p =
0.13). Subjects' age and years of education were not signifi-
cantly related to the likelihood theywanted to undergo genetic
testing at baseline (Table 1).
3.2.1. Hypothetical study 1: oral medication trial
In study 1 of an oral medication “thought to be very safe,”
29 (85%) of 34 respondents indicated they would participate
in the trial (Fig. 1). Twenty-four endorsed “the possible
benefits outweigh the risks of being made aware of genetic
status,” and 27 endorsed “to help future generations” as
reasons to participate. One subject provided “I would want to
know for my own future planning,” and another cited theAD mutation status at baseline and those not wanting to know their FAD
maybe want to know
status (n = 22)
Do not want to know their FAD
mutation status (n = 12)
7 (58%) p = 0.07
38.1 (9.5) p = 0.24
14.3 (2.8) p = 0.61
10 (83%) p = 0.82
Fig. 1. Percentage of subjects expressing an interest in undergoing revealing genetic testing in order to participate in clinical trials to prevent FAD of increasing
invasiveness, without or with (P) a 50% chance of receiving placebo.
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participate. Of the 5 subjects who were not interested in
participating, three endorsed concerns about the benefits not
outweighing the risks of knowing their status. There were no
statistically significant differences in whether a respondent
might participate based on spoken language, age, years of
education, gender, country of residence, employment status,
or whether the respondent had children or was planning to
have children.
When participants were asked to consider hypothetical
study 1 in the context of a 50% chance of receiving placebo,
the number of respondents willing to undergo testing and
participate dropped to 21 (62%, p = 0.02, Fig. 1) with 11
individuals electing not to participate (33%), and 2 respon-
dents not answering the question (5%). Of the eleven
individuals not willing to undergo a 50% chance or receiving
placebo, 6 provided acceptable risks of receiving placebo and
were “0%” (n = 3), “10%” (n = 2), and “25%” and “30%” (one
subject each).3.2.2. Hypothetical study 2: vaccine trial
Twenty (59%) respondents indicated they would partic-
ipate in Study 2 (Fig. 1). Seventeen endorsed “the possible
benefits outweigh the risks of being made aware of genetic
status” and 16 “to help future generations” as reasons. Of the
14 who were not willing to participate in this study, all
endorsed concerns regarding the risk outweighing the
benefits. Those willing were no different from those unwill-
ing based on gender, years of education, employment, or
whether the respondent had children or planned to have
children. English speakers (71%), however, more frequently
endorsed a willingness to participate than did Spanish
speakers (30%, p = 0.03), and those residing in the United
States (75%) more frequently endorsed a willingness to
participate than those living in Mexico, (22%, p = 0.006).
Additionally, those willing to participate in Hypotheticalstudy 2 were significantly younger than those choosing not to
participate (32.3 years vs. 39.6 years, p = 0.04).
For the vaccine study, the number of respondents willing
to participate increased non-significantly to 22 (65%, p =
0.75, Fig. 1) when asked to consider the trial with a 50%
possibility of random assignment to a placebo group. Of the
12 who refused participation, 10 endorsed concerns about
the risks of the study outweighing the benefits. Regarding an
acceptable chance of receiving placebo, 3 indicated “0%,” 1 a
“10%,” and 1 a “25%” chance. Of the 20 subjects who had
indicated a willingness to participate in a study without a
placebo arm, 4 declined when there was a 50% chance of
receiving placebo. Of the 14 who indicated they would not
participate without placebo, 6 indicated they would if they
had a 50% chance of being assigned to placebo. All endorsed
“the possible benefits outweigh the risks of being made
aware of genetic status” and “to help future generations” as
reasons to participate.
3.2.3. Hypothetical study 3: intravenous drug trial
Eighteen (53%) of 34 respondents indicated they would
participate in Trial 3 (Fig. 1). Seventeen endorsed “the possible
benefits outweigh the risks of being made aware of genetic
status” and 13 “to help future generations” as reasons to
participate. No differences between willing and unwilling
respondents were apparent with regard to language, gender,
age, years of education, or employment status. However, there
were statistically significant differences in whether respon-
dents were willing to participate when analyzing the data in
relation to country of residence or whether they had children.
Persons living in the United States, weremore likely to endorse
awillingness to participate (67%vs. 22%, p =0.02), and persons
with children more frequently endorsed a willingness to
participate than did those without children (75% vs. 33%,
p = 0.02).
The number of respondents who indicated they were
willing to participate in the intravenous drug study increased
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setting of a 50% possibility of randomization to placebo. Of
the 18 who indicated a willingness to participate without
placebo, 4 declined when there was a 50% chance of receiving
placebo. Of the 16 who refused the study without placebo, 6
said they would if there was a 50% chance of receiving
placebo. Of these 6, 5 endorsed “the possible benefits
outweigh the risks of being made aware of genetic status”
and “to help future generations” as motivations. Eleven of 14
persons who refused the study with placebo endorsed the
risks of the study outweighing the benefits as the reason. One
subject wrote “Being vaccinated every 3 mo for the rest of my
life would be hard for me and I would be scared of side
effects.” Regarding an acceptable chance of receiving placebo,
four indicated “0%,” four indicated “10%,” and one indicated
“25%.”3.2.4. Hypothetical study 4: neurosurgery trial
When asked about participation in the trial involving brain
surgery, 12 of 34 respondents (35%) indicated they would
participate (Fig. 1). Nine endorsed “the possible benefits
outweigh the risks of being made aware of genetic status,” and
11 endorsed “to help future generations” as reasons. One
indicated “I would want to wait until 5 years from the time I
am likely to die of AD,” andone indicated “I think that Iwould do
most anything that was reasonably safe and has been studied
well.” All but one of the 22 participants refusing participation
endorsed concerns regarding the risks outweighing the benefits.
There were no differences in whether or not a respondent
would participate in the trial based on language, gender, age,
years of education, country of residence, employment, or
baseline interest in participating in clinical trials. A greater
proportion of personswith children (50%) than personswithout
children (22%) expressed an interest in participating, although
this difference did not reach statistical significance (p = 0.09).
When respondents considered trial 4 in the setting of a
50% chance of random assignment to placebo, the number
willing to participate increased non-significantly to 14 (41%,
p = 0.55, Fig. 1). One respondent elected not to answer the
question (3%). Of the 11 subjects willing to participate in
Study 4 without the possibility of assignment to placebo, four
refused participation if there was a 50% chance of being
assigned to placebo. Of 22 who refused participation without
the possibility of assignment to placebo, 7 indicated a
willingness to participate if there was a 50% chance of being
assigned to placebo. Of these seven, 6 endorsed both
“the possible benefits outweigh the risks of being made
aware of genetic status” and “to help future generations” as
reasons. All but one of the 19 subjects who refused
participation when there was a chance of receiving placebo
endorsed concerns about the risks outweighing the benefits.
Specific reasons given were “This whole procedure seems
dangerous and painful,” “The risk of death for a placebo is too
high,” and “If anesthesia is involved, I want the treatment and
not the placebo.” Acceptable chances of receiving placebo
were given as “0%” by four, “5%” by two, “10%” by two, and
“40%” by one subject.
Overall, 22 of the 34 subjects completing the questionnaire
answered the same with regard to whether or not they would
participate in studies with a 50% chance of receiving placeboacross all trials. Of these, 13 said they would participate in all
trials and 9 said they would not participate in any.
4. Discussion
The purpose of the study was to explore the willingness to
undergo revealing genetic testing in the setting of clinical
trials for experimental interventions of FAD. These results
may be generalizable to prevention studies in other fully
penetrant autosomal dominant neurodegenerative disease of
adult onset such as Huntington's disease.
The availability of prevention studies might serve as
incentive for persons at risk for FAD to undergo genetic testing.
Nearly half of respondents expressed interest in undergoing
revealing genetic testing. The proportion willing to undergo
testing was increased in three out of four hypothetical clinical
trial scenarios, even when trials were placebo-controlled. In
two of the hypothetical studies, including trials of a vaccine and
of an intravenously infused medication, residing in the United
States (as opposed toMexico) was associatedwith higher rates
of interest in participation. For the infusedmedication trial and
a trial of neurosurgical intervention, persons with children
were more motivated, possibly related to their expressed
interest in helping future generations.
As the potential for complications increases, the number of
subjects interested in undergoing testing to participate de-
creases. Only trial 1 was explicitly described as safe, and only
trial 4 was explicitly described as being high risk. Surprisingly,
the number of respondents interested in participating in the
more invasive studies 2, 3, and 4 increased slightly when the
possibility of receiving placebo was introduced. Although this
may represent a random effect, some people may participate
out of altruism rather than for any possible benefit to
themselves, and respondents may have viewed the possibility
of receiving placebo as a reduction in the overall risk of
participation. The fact that the vast majority of these subjects
explicitly endorsed “to help future generations” as motivation
to participate supports this possibility. A few subjects unwilling
to participate in a study in which there was a 50% chance of
receiving placebo indicated a willingness to participate if the
risk was reduced to between 5% and 40%. This suggests that
trial designs in which the chance of receiving placebo is less
than 50% may increase enrollment.
Limitations of the study include the small sample size and
the highly selected nature of the population. All subjects had
previously participated in, or were currently participating in,
a comprehensive observational study of the presymptomatic
state in FAD and therefore represent a highly motivated
group. This is reflected in the high level of interest in
potentially undergoing genetic testing at baseline (44%),
which is substantially higher than the 8% previously observed
in a clinic-based study [12]. Therefore, the high level of
interest in participating in clinical trials in which genetic
status is revealed is unlikely to represent the opinion of the
general population at risk for FAD, which includes those who
have opted not to participate in observational studies.
An important aspect of our study was that the population
was largely Latino of Mexican origin. It is important to
understand the attitudes of this population that is typically
underrepresented in research but the applicability of our
results to other ethnic groups may be limited. In future
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ethnicities. Additionally, the majority of respondents were
female due to higher numbers of female participants in
the observational study. Rates of participation in genetic
studies are generally higher in women [14] although the
degree to which this applies to clinical trials of prevention is
unknown.
Although we exerted every effort to make the English and
Spanish versions of the questionnaire equivalent, the degree to
which we achieved this is unknown. It is therefore impossible
to eliminate language as a potential confounder or to determine
to what extent language or culture account for the observed
differences among persons from different nations. Unfortu-
nately, it is difficult to predict how such a bias might influence
the outcomes of this survey. Finally, the degree to which
subjects' responses on this hypothetical questionnaire predict
their real-life behavior is unknown. It is very possible that
persons at risk for FADwill responddifferentlywhen facedwith
actual trial opportunities.
Clinical trials for the prevention of FAD are underway
[11,15,16]. In order to avoid the necessity of revealing persons'
genetic status for enrollment, one possible study design is to
perform testing but not reveal the results to subjects, non-
randomly assigning all non-mutation carriers to placebo.
Although this design has important strengths, a potential
pitfall is that, should mutation carriers who do not want to
know their genetic status develop adverse effects thought to be
related to drug, they would (potentially incorrectly) infer
information they may not have wanted to receive.
Our data suggest that clinical trial designs in which persons
must confront their genetic status prior to enrollment
are feasible. However, in order to uphold the principle of
autonomy, these vulnerable subjects need to be thoroughly
educated prior to making decisions regarding participation.
Additionally, to uphold the principle of beneficence, study
designs to minimize the likelihood of being placed on placebo
and eventual provision of the drug (e.g., via open-label
extensions) must be considered.5. Conclusions
Our results indicate that the availability of trials to
prevent FAD, and possibly other fully penetrant autosomal
dominant neurodegenerative diseases of late onset, will
provide motivation for subjects to undergo revealing genetic
testing in all but the most invasive protocols. This suggests
that such studies in which genetic status is revealed are
feasible. Latinos living in the United States were more likely
to participate in the studies of intermediate invasiveness
than their counterparts in Mexico, possibly reflecting an
effect of the adoption of the vales of Western medicine in the
course of acculturation. Although the possibility of receiving
placebo can decrease subjects' willingness to participate,
this may not hold for interventions perceived to be more
dangerous and designs in which the risk of receiving placebo
is less than 50% can encourage participation. Altruism
appears to be an important factor influencing at-risk persons
desire to undergo genetic testing and participate. These
observations should provide guidance in the design of and
recruitment strategies for such prevention studies.Role of funding sources
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